EPA-logo-simplified-color

Does the New Alzheimer’s Drug Mean the End of Alzheimer’s? With Dr. Marwan Sabbagh, MD. Copy

In this episode of Evolving Past Alzheimer’s,  Dr. Nate Bergman speaks with Dr. Marwan Sabbagh,  clinical and research leader at the Cleveland Clinic’s Lou Ruvo Center for Brain Health. He is one of the doctors that saw patients in one of the trials that led to the FDA’s Accelerated (provisional) Approval of Aducanumab (Aduhelm).

In this episode, you will hear the argument in favor of Aducanumab. Dr. Sabbagh also talks through who he thinks might be a good candidate for Aducanumab, the drug’s known practical side effects, and how people might get access to the medication in the near future.

Listen in and let us know what you think!